Xarelto and Pradaxa Among the Most Highly-Marketed Drugs to Doctors and Teaching Hospitals

According to a joint study performed by The New York Times and the non-profit investigative journalism outfit Pro-Publica, blood thinning drugs Pradaxa and Xarelto rank among the top 20 pharmaceutical drugs that manufacturers are paying the most to promote, through meals, consulting work, and gifts to doctors in order to increase market share. The study found that in the second half of 2013, drug companies paid at least $6.93 million and $4.43 million for Xarelto and Pradaxa, respectively, for interactions with physicians and teaching hospitals. Dr. Joseph Ross, a medical professor from Yale University School of Medicine, commented on the study, explaining that almost all of these highly-marketed drugs can be labeled “me-too drugs,” as many do not represent large medical breakthroughs or new cures, but are rather “fairly redundant with other therapies already available.”

Real Time Analytics